9 / 32
Endpoint
EGFR
mutant
a
n = 13
EGFR
wild-type
n = 104
KRAS
mutant
n = 33
KRAS
wild-type
n = 67
INV ORR
TC2/3 or IC2/3, n (%)
4 (31%)
24 (23%)
10 (31%)
16 (24%)
mDOR, mo
(95% CI)
10.4 mo
(5.5, 17.5)
13.1 mo
(7.8, NE)
15.8 mo
(7.2, NE)
11.2 mo
(7.8, 16.5)
mPFS, mo
(95% CI)
7.6 mo
(1.4, 13.6)
7.7 mo
(4.7, 9.9)
9.8 mo
(4.9, 19.8)
7.1 mo
(3.9, 10.9)
Carcereny et al., BIRCH. WCLC 2017
BIRCH: ORR, DOR and PFS by mutation and
PD-L1 status
•
Investigator assessments.
•
a
Patients were considered to be EGFR mutant for the analysis if their tumor tested positive for at least one of the following: exon 19 deletions or insertions, L858R, exon 20 insertion, G719X, L861Q or S768I. Three patients
with a T790Mmutation were not included in this analysis; two of whom also had an exon 19 deletion.
•
TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD-L1–expressing cells; TC2/3 or IC2/3 = TC or IC ≥ 5% PD-L1–expressing cells, respectively.
•
Data cutoff date: August 7, 2017.